CN103239646B - Chinese medicine effective part composition for treating leucoderma and preparation method thereof - Google Patents
Chinese medicine effective part composition for treating leucoderma and preparation method thereof Download PDFInfo
- Publication number
- CN103239646B CN103239646B CN201310198014.4A CN201310198014A CN103239646B CN 103239646 B CN103239646 B CN 103239646B CN 201310198014 A CN201310198014 A CN 201310198014A CN 103239646 B CN103239646 B CN 103239646B
- Authority
- CN
- China
- Prior art keywords
- composition
- chinese medicinal
- treatment
- chinese medicine
- medicinal effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims description 8
- 210000000582 Semen Anatomy 0.000 claims abstract description 4
- 239000002994 raw material Substances 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound data:image/svg+xml;base64,PD94bWwgdmVyc2lvbj0nMS4wJyBlbmNvZGluZz0naXNvLTg4NTktMSc/Pgo8c3ZnIHZlcnNpb249JzEuMScgYmFzZVByb2ZpbGU9J2Z1bGwnCiAgICAgICAgICAgICAgeG1sbnM9J2h0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnJwogICAgICAgICAgICAgICAgICAgICAgeG1sbnM6cmRraXQ9J2h0dHA6Ly93d3cucmRraXQub3JnL3htbCcKICAgICAgICAgICAgICAgICAgICAgIHhtbG5zOnhsaW5rPSdodHRwOi8vd3d3LnczLm9yZy8xOTk5L3hsaW5rJwogICAgICAgICAgICAgICAgICB4bWw6c3BhY2U9J3ByZXNlcnZlJwp3aWR0aD0nMzAwcHgnIGhlaWdodD0nMzAwcHgnIHZpZXdCb3g9JzAgMCAzMDAgMzAwJz4KPCEtLSBFTkQgT0YgSEVBREVSIC0tPgo8cmVjdCBzdHlsZT0nb3BhY2l0eToxLjA7ZmlsbDojRkZGRkZGO3N0cm9rZTpub25lJyB3aWR0aD0nMzAwLjAnIGhlaWdodD0nMzAwLjAnIHg9JzAuMCcgeT0nMC4wJz4gPC9yZWN0Pgo8cGF0aCBjbGFzcz0nYm9uZC0wIGF0b20tMCBhdG9tLTEnIGQ9J00gMTMuNiwxNzUuMyBMIDEzMi44LDEwNi41JyBzdHlsZT0nZmlsbDpub25lO2ZpbGwtcnVsZTpldmVub2RkO3N0cm9rZTojM0I0MTQzO3N0cm9rZS13aWR0aDoyLjBweDtzdHJva2UtbGluZWNhcDpidXR0O3N0cm9rZS1saW5lam9pbjptaXRlcjtzdHJva2Utb3BhY2l0eToxJyAvPgo8cGF0aCBjbGFzcz0nYm9uZC0xIGF0b20tMSBhdG9tLTInIGQ9J00gMTMyLjgsMTA2LjUgTCAxNzIuNywxMjkuNicgc3R5bGU9J2ZpbGw6bm9uZTtmaWxsLXJ1bGU6ZXZlbm9kZDtzdHJva2U6IzNCNDE0MztzdHJva2Utd2lkdGg6Mi4wcHg7c3Ryb2tlLWxpbmVjYXA6YnV0dDtzdHJva2UtbGluZWpvaW46bWl0ZXI7c3Ryb2tlLW9wYWNpdHk6MScgLz4KPHBhdGggY2xhc3M9J2JvbmQtMSBhdG9tLTEgYXRvbS0yJyBkPSdNIDE3Mi43LDEyOS42IEwgMjEyLjcsMTUyLjYnIHN0eWxlPSdmaWxsOm5vbmU7ZmlsbC1ydWxlOmV2ZW5vZGQ7c3Ryb2tlOiNFODQyMzU7c3Ryb2tlLXdpZHRoOjIuMHB4O3N0cm9rZS1saW5lY2FwOmJ1dHQ7c3Ryb2tlLWxpbmVqb2luOm1pdGVyO3N0cm9rZS1vcGFjaXR5OjEnIC8+Cjx0ZXh0IHg9JzIzOS45JyB5PScxOTUuMycgY2xhc3M9J2F0b20tMicgc3R5bGU9J2ZvbnQtc2l6ZTo0MHB4O2ZvbnQtc3R5bGU6bm9ybWFsO2ZvbnQtd2VpZ2h0Om5vcm1hbDtmaWxsLW9wYWNpdHk6MTtzdHJva2U6bm9uZTtmb250LWZhbWlseTpzYW5zLXNlcmlmO3RleHQtYW5jaG9yOnN0YXJ0O2ZpbGw6I0U4NDIzNScgPk88L3RleHQ+Cjx0ZXh0IHg9JzI2Ny41JyB5PScxOTUuMycgY2xhc3M9J2F0b20tMicgc3R5bGU9J2ZvbnQtc2l6ZTo0MHB4O2ZvbnQtc3R5bGU6bm9ybWFsO2ZvbnQtd2VpZ2h0Om5vcm1hbDtmaWxsLW9wYWNpdHk6MTtzdHJva2U6bm9uZTtmb250LWZhbWlseTpzYW5zLXNlcmlmO3RleHQtYW5jaG9yOnN0YXJ0O2ZpbGw6I0U4NDIzNScgPkg8L3RleHQ+Cjwvc3ZnPgo= data:image/svg+xml;base64,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 CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances data:image/svg+xml;base64,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 data:image/svg+xml;base64,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 O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 230000000240 adjuvant Effects 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 210000004369 Blood Anatomy 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 210000003491 Skin Anatomy 0.000 abstract description 3
- 210000003734 Kidney Anatomy 0.000 abstract description 2
- 210000004185 Liver Anatomy 0.000 abstract description 2
- 231100000486 side effect Toxicity 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 241000219784 Sophora Species 0.000 abstract 1
- 241001671219 Stachyurus Species 0.000 abstract 1
- 241000209149 Zea Species 0.000 abstract 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 abstract 1
- 230000003213 activating Effects 0.000 abstract 1
- 235000005822 corn Nutrition 0.000 abstract 1
- 235000005824 corn Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 238000009499 grossing Methods 0.000 abstract 1
- 206010047642 Vitiligo Diseases 0.000 description 7
- 206010025421 Macule Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound data:image/svg+xml;base64,<?xml version='1.0' encoding='iso-8859-1'?>
<svg version='1.1' baseProfile='full'
              xmlns='http://www.w3.org/2000/svg'
                      xmlns:rdkit='http://www.rdkit.org/xml'
                      xmlns:xlink='http://www.w3.org/1999/xlink'
                  xml:space='preserve'
width='300px' height='300px' viewBox='0 0 300 300'>
<!-- END OF HEADER -->
<rect style='opacity:1.0;fill:#FFFFFF;stroke:none' width='300.0' height='300.0' x='0.0' y='0.0'> </rect>
<path class='bond-0 atom-0 atom-1' d='M 47.8,112.6 L 63.3,112.6' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-0 atom-0 atom-1' d='M 63.3,112.6 L 78.9,112.6' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-1 atom-1 atom-2' d='M 83.0,114.9 L 89.4,103.8' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-1 atom-1 atom-2' d='M 89.4,103.8 L 95.8,92.8' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-1 atom-1 atom-2' d='M 74.7,110.2 L 81.1,99.1' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-1 atom-1 atom-2' d='M 81.1,99.1 L 87.5,88.0' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-2 atom-1 atom-3' d='M 78.9,112.6 L 102.5,153.6' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-3 atom-3 atom-4' d='M 102.5,153.6 L 149.9,153.6' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-4 atom-4 atom-5' d='M 149.9,153.6 L 149.9,140.0' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-4 atom-4 atom-5' d='M 149.9,140.0 L 149.9,126.4' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-5 atom-4 atom-6' d='M 149.9,153.6 L 149.9,201.0' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-8 atom-4 atom-9' d='M 149.9,153.6 L 197.3,153.6' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-6 atom-6 atom-7' d='M 149.9,201.0 L 162.9,208.5' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-6 atom-6 atom-7' d='M 162.9,208.5 L 175.9,216.0' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-7 atom-6 atom-8' d='M 147.6,196.9 L 134.6,204.4' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-7 atom-6 atom-8' d='M 134.6,204.4 L 121.6,211.9' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-7 atom-6 atom-8' d='M 152.3,205.1 L 139.3,212.6' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-7 atom-6 atom-8' d='M 139.3,212.6 L 126.3,220.1' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-9 atom-9 atom-10' d='M 197.3,153.6 L 221.0,112.6' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-10 atom-10 atom-11' d='M 221.0,112.6 L 236.5,112.6' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-10 atom-10 atom-11' d='M 236.5,112.6 L 252.1,112.6' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-11 atom-10 atom-12' d='M 225.1,110.2 L 218.7,99.1' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-11 atom-10 atom-12' d='M 218.7,99.1 L 212.3,88.0' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-11 atom-10 atom-12' d='M 216.9,114.9 L 210.5,103.8' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-11 atom-10 atom-12' d='M 210.5,103.8 L 204.1,92.8' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<text x='13.6' y='122.0' class='atom-0' style='font-size:18px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#E84235' >H</text>
<text x='25.8' y='122.0' class='atom-0' style='font-size:18px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#E84235' >O</text>
<text x='96.9' y='81.0' class='atom-2' style='font-size:18px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#E84235' >O</text>
<text x='144.3' y='115.7' class='atom-5' style='font-size:18px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#E84235' >O</text>
<text x='157.3' y='115.7' class='atom-5' style='font-size:18px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#E84235' >H</text>
<text x='185.3' y='234.2' class='atom-7' style='font-size:18px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#E84235' >O</text>
<text x='198.4' y='234.2' class='atom-7' style='font-size:18px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#E84235' >H</text>
<text x='103.2' y='234.2' class='atom-8' style='font-size:18px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#E84235' >O</text>
<text x='262.7' y='122.0' class='atom-11' style='font-size:18px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#E84235' >O</text>
<text x='275.8' y='122.0' class='atom-11' style='font-size:18px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#E84235' >H</text>
<text x='191.6' y='81.0' class='atom-12' style='font-size:18px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#E84235' >O</text>
</svg>
 data:image/svg+xml;base64,<?xml version='1.0' encoding='iso-8859-1'?>
<svg version='1.1' baseProfile='full'
              xmlns='http://www.w3.org/2000/svg'
                      xmlns:rdkit='http://www.rdkit.org/xml'
                      xmlns:xlink='http://www.w3.org/1999/xlink'
                  xml:space='preserve'
width='85px' height='85px' viewBox='0 0 85 85'>
<!-- END OF HEADER -->
<rect style='opacity:1.0;fill:#FFFFFF;stroke:none' width='85.0' height='85.0' x='0.0' y='0.0'> </rect>
<path class='bond-0 atom-0 atom-1' d='M 10.6,31.4 L 16.2,31.4' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-0 atom-0 atom-1' d='M 16.2,31.4 L 21.9,31.4' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-1 atom-1 atom-2' d='M 23.0,32.1 L 25.4,27.9' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-1 atom-1 atom-2' d='M 25.4,27.9 L 27.8,23.8' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-1 atom-1 atom-2' d='M 20.7,30.7 L 23.1,26.6' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-1 atom-1 atom-2' d='M 23.1,26.6 L 25.5,22.5' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-2 atom-1 atom-3' d='M 21.9,31.4 L 28.6,43.0' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-3 atom-3 atom-4' d='M 28.6,43.0 L 42.0,43.0' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-4 atom-4 atom-5' d='M 42.0,43.0 L 42.0,38.0' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-4 atom-4 atom-5' d='M 42.0,38.0 L 42.0,32.9' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-5 atom-4 atom-6' d='M 42.0,43.0 L 42.0,56.4' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-8 atom-4 atom-9' d='M 42.0,43.0 L 55.4,43.0' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-6 atom-6 atom-7' d='M 42.0,56.4 L 46.7,59.1' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-6 atom-6 atom-7' d='M 46.7,59.1 L 51.5,61.9' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-7 atom-6 atom-8' d='M 41.3,55.2 L 36.6,58.0' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-7 atom-6 atom-8' d='M 36.6,58.0 L 31.8,60.7' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-7 atom-6 atom-8' d='M 42.7,57.6 L 37.9,60.3' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-7 atom-6 atom-8' d='M 37.9,60.3 L 33.2,63.0' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-9 atom-9 atom-10' d='M 55.4,43.0 L 62.1,31.4' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-10 atom-10 atom-11' d='M 62.1,31.4 L 67.7,31.4' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-10 atom-10 atom-11' d='M 67.7,31.4 L 73.3,31.4' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-11 atom-10 atom-12' d='M 63.2,30.7 L 60.9,26.6' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-11 atom-10 atom-12' d='M 60.9,26.6 L 58.5,22.5' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-11 atom-10 atom-12' d='M 60.9,32.1 L 58.5,27.9' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-11 atom-10 atom-12' d='M 58.5,27.9 L 56.1,23.8' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<text x='2.8' y='34.4' class='atom-0' style='font-size:6px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#E84235' >H</text>
<text x='6.7' y='34.4' class='atom-0' style='font-size:6px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#E84235' >O</text>
<text x='26.8' y='22.8' class='atom-2' style='font-size:6px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#E84235' >O</text>
<text x='40.2' y='32.6' class='atom-5' style='font-size:6px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#E84235' >O</text>
<text x='44.3' y='32.6' class='atom-5' style='font-size:6px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#E84235' >H</text>
<text x='51.8' y='66.1' class='atom-7' style='font-size:6px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#E84235' >O</text>
<text x='55.9' y='66.1' class='atom-7' style='font-size:6px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#E84235' >H</text>
<text x='28.6' y='66.1' class='atom-8' style='font-size:6px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#E84235' >O</text>
<text x='73.7' y='34.4' class='atom-11' style='font-size:6px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#E84235' >O</text>
<text x='77.8' y='34.4' class='atom-11' style='font-size:6px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#E84235' >H</text>
<text x='53.6' y='22.8' class='atom-12' style='font-size:6px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#E84235' >O</text>
</svg>
 OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000009002 tong-qiao-huo-xue Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- 230000036740 Metabolism Effects 0.000 description 1
- 206010062080 Pigmentation disease Diseases 0.000 description 1
- 208000006641 Skin Disease Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000003203 everyday Effects 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003340 mental Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Abstract
The invention discloses a Chinese medicine effective part composition for treating leucoderma. The Chinese medicine effective part composition is prepared from semen oroxyli, medulla of stachyurus, sophora fruit, corn stigma and cortex periplocae as raw materials according to certain parts by weight. The Chinese medicine effective part composition disclosed by the invention can be prepared into a medicament for treating leucoderma. The Chinese medicine effective part composition has the effects of activating blood and removing blood stasis, dredging collaterals and smoothing skin, tonifying liver and kidney, and nourishing the blood to expel wind, can be used for significantly treating the leucoderma, and has the advantages of being free of toxic and side effects, and high in safety.
Description
Technical field
The present invention relates to Chinese medicine composition field, be specifically related to one and be used for the treatment of leukodermic Chinese medicinal effective-part composition and preparation method thereof.
Background technology
Vitiligo is the abnormal common skin diseases of a kind of metabolism of pigment.Without obvious inducement, doctor trained in Western medicine is thought may be relevant with heredity, autoimmune, endocrine and Nervous and Mental Factors.Due to etiology unknown, treatment is also without desirable method.The conventional therapy of the traditional Chinese medical science is to take TONGQIAOHUOXUE Decoction or LIUWEI DIHUANG TANG, SIWU TANG etc.
Summary of the invention
The object of the present invention is to provide one for the preparation of the leukodermic Chinese medicinal effective-part composition for the treatment of, this Chinese medicinal effective-part composition can be treated vitiligo fast and effectively, has advantages of that therapeutic effect is remarkable, safe, has no side effect.
Above-mentioned purpose of the present invention is achieved by the following technical programs:
The leukodermic Chinese medicinal effective-part composition for the treatment of of the present invention is by making according to the raw material of mass fraction meter as follows: Semen Oroxyli 28, Medulla Stachyuri (Medulla Helwingiae) 25, the Fructus Sophorae 20, Stigma Maydis 15 and Cortex Periplocae 12.
The dosage form that the present invention treats the applicable processing of leukodermic Chinese medicinal effective-part composition is oral liquid.
The preparation method of the leukodermic Chinese medicinal effective-part composition for the treatment of of the present invention comprises the steps:
(1) each Chinese medicinal components is pulverized, added 12 times of water gagings, decoct 3 times, decoct 3 hours at every turn; Filter merging filtrate after decocting liquid, be evaporated to relative concentration and be 1.15 cream, add ethanol, making it contain alcohol amount is 62%, and hold over night reclaims ethanol, concentrated;
(2) concentrated solution after concentrated is added to applicable adjuvant according to conventional formulation technique, be processed into oral liquid.
Compared with prior art, the present invention has following beneficial effect:
(1) compositions of the present invention has effect of nourishing the liver and kidney, yin nourishing hair growth promoting, invigorating qi and benefiting blood, sensible blood stasis dispelling, through test, and can fast treating vitiligo.The present invention is that to make oral liquid for oral administration, compared with traditional external-use lotion or acupuncture and moxibustion treatment, can cure faster vitiligo.
(2) present composition has no side effect.
(3) preparation method of the present composition is simple, and yield is high, has effectively kept the effective ingredient of medicine.
Detailed description of the invention
Further explain the present invention below in conjunction with embodiment, but embodiment does not limit in any form to the present invention.
embodiment 1
Get Semen Oroxyli 28g, Medulla Stachyuri (Medulla Helwingiae) 25g, Fructus Sophorae 20g, Stigma Maydis 15g and Cortex Periplocae 12g, be crushed to coarse powder, add 10 times of water gagings, decoct 3 times, decoct 2 hours at every turn; Filter merging filtrate after decocting liquid, be evaporated to relative concentration and be 1.3 cream, add ethanol, making it contain alcohol amount is 60%, and hold over night reclaims ethanol, obtain concentrated solution 1000ml, get simple syrup, add above-mentioned concentrated solution, and with citric acid adjust pH to 4, adding distil water is to 5000ml, stir, after fine straining, be distributed in 15ml vial, be packaged to be oral liquid.
This product is brown clear liquid, places in half a year and does not produce muddiness, pH approximately 4, total solid 5% left and right.
embodiment 2
Clinical observation patient 600 examples, patient all has obvious vitiligo clinical symptoms and makes a definite diagnosis through clinicist.
Patient is divided into three groups, first group of oral liquid that oral embodiment 1 makes, every day sooner or later respectively once, each 15ml.Take 20 days.Second group of oral TONGQIAOHUOXUE Decoction, dose is followed the doctor's advice.Take LIUWEI DIHUANG TANG for the 3rd group, dose is followed the doctor's advice.
After 20 days, statistical result is in table 1.
Criterion of therapeutical effect: effectively comprise two grades.One-level is that white macula disappears or reduces, and the gross area that recovers the colour of skin is greater than 70%; Secondary be white macula dwindle recover normal colour of skin area be less than 70%, in white macula, have a large amount of pigmentations, grow pigment island or rubescent dimmed person.Invalid referring to after treatment, symptom and sign fail to improve, and even increase the weight of.
Table 1
| Group | Number of cases | Effective | Invalid | Obvious effective rate (%) |
| 1 | 200 | 198 | 2 | 99 |
| 2 | 200 | 101 | 99 | 50.5 |
| 3 | 200 | 124 | 76 | 62% |
Known by table 1, the oral liquid that embodiment 1 obtains has specially good effect in treatment vitiligo.Chinese medicine of the present invention was made oral liquid after 20 days, can be within half a year highly significant healing or alleviate vitiligo disease and its effect is better than at present conventional TONGQIAOHUOXUE Decoction and LIUWEI DIHUANG TANG.Through follow-up following up a case by regular visits to, all there is not the symptom of recurrence in the above-mentioned patient who takes medicine described in embodiment 1.
embodiment 3
The oral liquid administration ICR mice that uses embodiment 1 to make, body weight 20 ~ 25g, male and female half and half, successive administration 90d.
Through prerun, the lotion toxicity that embodiment 1 makes is very low, does not measure LD50, measures therefore mice is carried out to maximum dosage-feeding on the one.Maximum dosage-feeding is 100ml/d, observes none example and be poisoned to death after 90 days, and all healthy survival, proves that the oral liquid that compositions of the present invention is made can not cause toxic and side effects to human body thus.
Claims (4)
1. the leukodermic Chinese medicinal effective-part composition for the treatment of, is characterized in that by making according to the raw material of mass fraction meter as follows: Semen Oroxyli 28, Medulla Stachyuri (Medulla Helwingiae) 25, the Fructus Sophorae 20, Stigma Maydis 15 and Cortex Periplocae 12.
2. the leukodermic Chinese medicinal effective-part composition for the treatment of according to claim 1, is characterized in that described Chinese medicinal effective-part composition makes oral liquid.
3. the preparation method for the treatment of leukodermic Chinese medicinal effective-part composition described in claim 1 or 2, is characterized in that comprising the steps:
(1) each Chinese medicinal components is pulverized, added 10 times of water gagings, decoct 3 times, decoct 2 hours at every turn; Filter merging filtrate after decocting liquid, be evaporated to relative concentration and be 1.3 cream, add ethanol, making it contain alcohol amount is 60%, and hold over night reclaims ethanol, concentrated;
(2) concentrated solution after concentrated is added to applicable adjuvant according to conventional formulation technique, be processed into oral liquid.
4. the application of Chinese medicinal effective-part composition described in claim 1 or 2, is characterized in that described Chinese medicinal effective-part composition is for the preparation of the leukodermic medicine for the treatment of.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310198014.4A CN103239646B (en) | 2013-05-26 | 2013-05-26 | Chinese medicine effective part composition for treating leucoderma and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310198014.4A CN103239646B (en) | 2013-05-26 | 2013-05-26 | Chinese medicine effective part composition for treating leucoderma and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103239646A CN103239646A (en) | 2013-08-14 |
| CN103239646B true CN103239646B (en) | 2014-08-06 |
Family
ID=48919749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310198014.4A Expired - Fee Related CN103239646B (en) | 2013-05-26 | 2013-05-26 | Chinese medicine effective part composition for treating leucoderma and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103239646B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105687358A (en) * | 2016-03-30 | 2016-06-22 | 王银法 | Medicine for treating vitiligo |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1824247A (en) * | 2005-12-22 | 2006-08-30 | 夏金陵 | Composition formula for treating leucoderma and its preparation method |
| CN102048872A (en) * | 2010-11-24 | 2011-05-11 | 荣成市新技术应用研究所 | Chinese medicinal composition for treating leucoderma |
-
2013
- 2013-05-26 CN CN201310198014.4A patent/CN103239646B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1824247A (en) * | 2005-12-22 | 2006-08-30 | 夏金陵 | Composition formula for treating leucoderma and its preparation method |
| CN102048872A (en) * | 2010-11-24 | 2011-05-11 | 荣成市新技术应用研究所 | Chinese medicinal composition for treating leucoderma |
Non-Patent Citations (4)
| Title |
|---|
| 中医治疗白癜风的研究进展;魏飞等;《广西中医药》;20120831;第35卷(第4期);第4-5页 * |
| 中医治疗白癜风证型和方药分析;司富春等;《世界中西医结合杂志》;20121231;第7卷(第8期);第709-712页 * |
| 司富春等.中医治疗白癜风证型和方药分析.《世界中西医结合杂志》.2012,第7卷(第8期),第709-712页. |
| 魏飞等.中医治疗白癜风的研究进展.《广西中医药》.2012,第35卷(第4期),第4-5页. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103239646A (en) | 2013-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104706953A (en) | Traditional Chinese medicine preparation for treating chronic cervicitis | |
| CN103239646B (en) | Chinese medicine effective part composition for treating leucoderma and preparation method thereof | |
| CN105343847A (en) | Traditional Chinese medicine composition for treating eczema containing folium artemisiae argyi and preparing method thereof | |
| CN103239605B (en) | Chinese medicine effective part composition for treating hyperostosis and preparation method of Chinese medicine effective part composition | |
| CN106581299B (en) | Traditional Chinese medicine composition for improving kidney qi deficiency of middle-aged and old people and application thereof | |
| CN102526385B (en) | Medicament for treating climacteric syndrome | |
| CN102526252B (en) | Mongolian medicine pillow for treating cervical spondylosis | |
| CN103565986B (en) | Chinese medicine active part composition for treating Reynolds disease and preparation method thereof | |
| CN103239543B (en) | Chinese medicine effective part composition for treating gastroptosis and preparation method of Chinese medicine effective part composition | |
| CN103239571B (en) | Chinese medicine effective part composition for treating alopecia areata and preparation method thereof | |
| CN104435491A (en) | Effective part composition of traditional Chinese medicine for treating parkinson disease and preparation method of effective part composition | |
| CN103432247B (en) | Traditional Chinese medicine effective part composition for treating ischemic stroke and preparation method thereof | |
| CN103432204B (en) | Traditional Chinese medicine effective part composition for treating schizophrenia and preparation method thereof | |
| CN103417900B (en) | Composition of effective part of traditional Chinese medicine and preparation method of composition | |
| CN105688139A (en) | Traditional Chinese medicine composition for treating scalp folliculitis | |
| CN105796860A (en) | Quick-acting bone setting Yi medicine | |
| CN101983712A (en) | Novel medicament for treating coronary heart disease | |
| CN105169342A (en) | Traditional Chinese medicine composition for treating eczema and preparation method thereof | |
| CN104815132A (en) | External lotion for treating low back and leg pain and preparation method | |
| CN103463170B (en) | Hyperosteogeny treatment traditional Chinese medicine effective fraction composition and preparation method thereof | |
| CN103432252A (en) | Traditional Chinese medicine granule for treating ox influenza and preparation method thereof | |
| CN103239671B (en) | Chinese medicine effective part composition for treating climacteric syndrome and preparation method of Chinese medicine effective part composition | |
| CN103432212A (en) | Traditional Chinese medicine effective part composition for treating sciatica and preparation method thereof | |
| CN102552503A (en) | Traditional Chinese medicine powder used for treating cervical erosion | |
| CN101732408B (en) | Chinese medicament for treating angitis and limb angiopathy and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EXPY | Termination of patent right or utility model | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140806 Termination date: 20150526 |